Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Note that the Masimo trade secret lawsuit against Apple is separate from both an ITC injunction preventing the sale of Apple ...

Apple and Masimo's patent and trade secret dispute has ... excluding Apple Watches with a blood oxygen sensor. Apple redesigned and got Customs approval to continue sales by January 2024.

IRVINE, Calif. (AP) — IRVINE, Calif. (AP) — Masimo Corp. (MASI) on Tuesday reported third-quarter earnings of $9.8 million. On a per-share basis, the Irvine, California-based company said it ...

Masimo Corporation (NASDAQ:MASI) is a global medical technology company specializing in noninvasive patient monitoring technologies. It develops and manufactures monitoring devices, sensors ...

In this article, we are going to take a look at where Masimo Corporation (NASDAQ:MASI) stands against other most promising medical stocks. The healthcare sector depends on medical technology ...

Piper Sandler raised the firm’s price target on Masimo (MASI) to $180 from $165 and keeps an Overweight rating on the shares. The firm notes the company announced Q3 revenue of $505M finished ...

Ladies and gentlemen, good afternoon, and welcome to Masimo's Third Quarter 2024 Earnings ... continue to benefit from the relocation of our sensor manufacturing to Malaysia in combination with ...

Masimo MASI is set to give its latest quarterly earnings report on Tuesday, 2024-11-05. Here's what investors need to know before the announcement. Analysts estimate that Masimo will report an ...

The FDA has only approved one medical wearable that provides continuous oxygen saturation (SpO2) and pulse rate tracking: the Masimo W1 Medical watch. “If you really want a wearable that’s ...

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO ...